Welcome to the CRL Insurer Services blog. From big data and insurtech to accelerated underwriting and self-service products, the world of life insurance is moving at an unprecedented pace. We are confident that mortality data and insurance industry capabilities will continue to evolve, and seek to provide relevant expertise and updates to our valued clients.
As we continue to provide lab, data, and underwriting services through the CRL Insurers Business Unit, we look forward to sharing updates with you here. Check out the latest posts below from our dedicated team of medical directors and industry leaders, who provide commentary on timely topics, innovative services and solutions, and the existing database of CRL expertise.
Dr. Michael Fulks, Consulting Medical Director, details a new study showcasing improved outcomes for pancreatic cancer patients through the use… Read More
Tags: Cancer, Life Insurance, Pancreatic cancer, Study
Consulting medical director Michael Fulks, MD, comments on recent changes to the leading causes of death because of COVID-19, drugs,… Read More
Tags: Cancer, Covid 19, Drug overdose, Life Insurance, Mortality
The conclusions of the Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference were recently published.1 This expert panel started with… Read More
Tags: eGFR, Kidney, Life Insurance, Mortality, Risk
As most physicians and many families can attest, coronary artery bypass graft (CABG) patients often show memory issues and other… Read More
Tags: Bypass, Cognitive, Insurance, Memory, Underwriting
The Insurers team is excited to share an update with our readers on CRL PLUS Rx™, a service to help… Read More
Tags: Insurance, Lab data, Plus Rx, Underwriting
It’s a simple concept: the more people you can label as having a condition for which you provide support (as… Read More
Tags: Diabetes, Insurance, Mortality, Study, Underwriting
Major depression is a common and serious illness, affecting up to 10% of the population at any given time. Unfortunately,… Read More
Tags: Depression, Insurance, Mental illness, Psilocybin, Underwriting
Dr. Michael Fulks comments on the results of a recent study of Donanemab, an antibody that targets the amyloid-β (Aβ)… Read More
Tags: Alzheimers, Cardiovascular, Dementia, Risk
CRL Chief Scientific Officer Dr. Robert Stout discusses the lasting impact of COVID-19 infection in both symptomatic and asymptomatic patients…. Read More
Tags: Covid 19, Covid 19 Crisis, Laboratory, Life Insurance, Mortality
By 2018, over 42% of US adults were obese (BMI 30+) with little variation by age and sex, and almost… Read More
Tags: Bmi, Insurance, Life Insurance, Obesity, Type 2 Diabetes